Azelast

Quick links to important sections

Azelast

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Azelast

Quick Facts

Property Description
Active ingredient Azelastine Hydrochloride
Form Aqueous Solution (Nasal Spray, Ophthalmic Solution)
Pharmacological class Selective Histamine H1-receptor Antagonist
Common purpose Localized relief of allergy symptoms
Origin Synthetic Phthalazine derivative

What Type of Medicine is Azelast? (Definition and Classification)

Azelast is a pharmaceutical preparation that utilizes the active ingredient Azelastine Hydrochloride, a synthetic chemical compound classified chemically as a Phthalazine derivative. It is fundamentally categorized as a Second-Generation Antihistamine and belongs to the Selective Histamine H1-receptor Antagonist pharmacological class.

The primary function of Azelastine is to block the effects of histamine released during an allergic reaction. Azelastine possesses dual properties as both an antihistamine and a mast-cell stabilizer. This means the medication is structurally and functionally designed to address allergy symptoms not just by blocking the signal, but also by regulating the immune cells that initiate the allergic cascade. The medication is used to provide rapid symptomatic relief through local administration.

Form, Origin, and General Benefit

Azelastine is formulated as an Aqueous Solution designed for local treatment, primarily delivered via the Intranasal (nasal spray) or Ophthalmic (eye drops) Route of Administration. Azelastine is available in forms intended for local, non-systemic use. This strategic formulation is a key differentiator from oral antihistamines, focusing on direct tissue relief.

This strategy of local application provides a significant general benefit by delivering a rapid, high concentration of the active ingredient directly to the affected tissues. The medication is commonly used in scenarios requiring immediate intervention for localized allergic discomfort. This method allows for targeted anti-allergic relief, ensuring the medicine is concentrated at the point of irritation for the management of localized symptoms.

What side effects are possible with Azelast?

Possible Side Effects and Safety Information

The safety profile of Azelastine, based on official regulatory classifications, is primarily defined by localized reactions related to its route of administration and systemic effects typical of its pharmacological class. All documented adverse reactions are categorized by frequency and the body system affected, consistent with government regulatory standards.

Frequency-Classified Adverse Reactions

Official labeling classifies adverse reactions based on how often they have been reported in clinical trials:

  • Very Common: For the ophthalmic solution, transient burning or stinging at the application site is a commonly observed effect.
  • Common: The nasal spray formulation is associated with effects such as bitter taste (dysgeusia), headache, nasal discomfort, and somnolence (drowsiness). Epistaxis (nosebleed) is also listed as a common respiratory effect.
  • Rare: Documented reactions in the Immune System Disorders category, such as certain hypersensitivity reactions (e.g., rash), are classified as rare.

Systemic Safety Considerations

Adverse effects are grouped into system-organ classes. The most frequently involved systems include Nervous System Disorders (drowsiness, headache) and Gastrointestinal Disorders (bitter taste). Due to the potential for somnolence, official labels include a safety note regarding potential impairment of mental alertness and physical performance. Furthermore, a high-level safety constraint is documented regarding the potential for the medicine to potentiate the effects of other Central Nervous System (CNS) depressants, including alcohol.

Population-Specific Safety Notes

The established safety parameters for Azelastine define specific age requirements. The nasal spray is established for use in children aged 6 years and older for certain indications, and the ophthalmic solution is established for children aged 3 years and older. Caution is also noted in regulatory documents regarding use during pregnancy and lactation due to animal study findings.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory profile for Azelastine is primarily defined by the risks associated with accidental oral ingestion of the non-oral solution. Overdose reactions are generally not anticipated when the medication is used via the intended nasal or ocular routes of administration.

Documented Overdose Manifestations

Overdosage resulting in high systemic exposure may cause Central Nervous System (CNS) disturbances. The expected manifestations documented in regulatory materials include drowsiness, excitation, and tremor. In severe cases of intoxication, these CNS effects may escalate to include convulsions or coma. The regulatory profile also notes potential cardiovascular effects, such as tachycardia (increased heart rate) and hypotension (low blood pressure).

Emergency Actions and Management

In the event of a suspected overdose or accidental ingestion, the mandatory action is to seek immediate medical help or contact a Poison Control Center right away. This urgent action is emphasized due to the risk of serious adverse effects in children following oral ingestion of non-oral antihistamine formulations. Regulatory documentation confirms that no specific antidote is known. Therefore, treatment is strictly symptomatic and supportive, and may involve interventions like gastric lavage if the overdose is determined to be recent.

Therapeutic Uses of Azelast

The primary therapeutic role of Azelastine involves providing localized symptomatic relief for conditions involving inflammatory or irritative states of the nasal passages and eyes. Azelastine is commonly used across conditions presenting with acute or episodic symptom patterns linked to allergies. This supports patients during difficult episodes by contributing to easing the overall symptom load.


Comprehensive Relief for Allergic and Non-Allergic Rhinitis

This domain addresses the primary use of the nasal spray, which is applied across conditions marked by increased physiological stress in the nose, including seasonal and perennial allergic rhinitis, as well as vasomotor rhinitis. The medication is used to manage the distressing cluster of nasal symptoms such as frequent sneezing, runny nose, and it may assist with addressing nasal congestion and post-nasal drip. This provides symptomatic support that helps improve day-to-day comfort and assists with maintaining functional stability when symptoms interfere with routine activities. Its application is relevant for these seasonal, perennial, and vasomotor conditions.

“Azelastine is commonly used in situations where symptoms may become more disruptive during flare-ups, supporting patients during symptomatic periods.”

Quick Fact: Relief for Nasal Congestion

Azelastine is relevant for easing symptoms that create noticeable physiological strain, making it an appropriate option in symptomatic management when nasal congestion is present.


Targeted Management of Allergic Ocular Irritation

This domain focuses on the targeted relief provided by the ophthalmic formulation for symptoms related to the eye surface, particularly in cases of Allergic Conjunctivitis. It is applied across domains where additional symptomatic support is needed to help address intense eye itching and excessive watery eyes. The localized focus of relief supports the patient during difficult episodes by easing the distress and assisting with maintaining functional stability when symptoms are more noticeable.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Official Regulatory Eligibility Profile

The regulatory eligibility profile for Azelastine is defined by age, physiological status, and the single absolute exclusion of hypersensitivity. The medicine is contraindicated in patients with a known hypersensitivity or allergy to azelastine hydrochloride or any of the product’s inactive components.

Indication Minimum Established Age
Seasonal Allergic Rhinitis 5 years
Perennial Allergic Rhinitis 6 months (select formulations)
Vasomotor Rhinitis 12 years
Allergic Conjunctivitis 3 years

Use is not established in populations below the minimum age thresholds listed above for the respective indications. Elderly patients are generally included in the adult population, though no specific data are available for those aged 65 and over.

Use during pregnancy and lactation is designated as conditional, permitted only if the potential benefit justifies the potential risks to the fetus or nursing infant, as Azelastine is excreted into human milk. Furthermore, the medicine must be used with caution in patients with renal impairment due to the potential for increased systemic exposure. Caution is also advised before engaging in activities requiring complete mental alertness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope Official Regulatory Statement
Medicinal product categories with documented interactions Central Nervous System (CNS) Depressants; Monoamine Oxidase Inhibitors (MAOIs)
Specific interacting medicines (if explicitly listed) Cimetidine; Alcohol (Ethanol); Isocarboxazid, Phenelzine, Tranylcypromine
Mechanistic basis of interactions Pharmacokinetic interaction leading to altered plasma concentrations; Pharmacodynamic interaction leading to additive effects
Interaction-related restrictions Concurrent use with alcohol and CNS depressants must be avoided; Co-administration with MAOIs should be avoided.

Interaction Classifications (High-Level)

The official prescribing information organizes interaction patterns into two critical categories:

  • Pharmacodynamic Interaction: Co-administration with Alcohol and CNS Depressants is restricted due to the potential for additive CNS depressant effects. This formal restriction is documented to prevent further reduction in alertness and impairment of central nervous system performance. Certain MAOIs are also advised to be avoided due to the predicted risk of increased antimuscarinic effects.
  • Pharmacokinetic Interaction: The substance Cimetidine is explicitly documented as causing a significant exposure-modifying interaction. Studies show Cimetidine substantially increases the systemic concentration of Azelastine, classifying it as a substance that interferes with clearance.

The regulatory documents define the product’s interaction structure through mandatory constraints against concurrent use based on additive effects and a specific, documented instance of clearance interference.

Mechanism of Action

Azelastine functions primarily as a selective histamine H1-receptor antagonist. It competitively binds to and blocks the H1-receptors located on peripheral target cells, including those on vascular endothelium and nerve tissue. This inhibitory interaction prevents the activation of these G-protein coupled receptors by endogenous histamine, thereby interrupting the subsequent intracellular signaling cascade typically mediated by phospholipase C and the phosphatidylinositol pathway.

Simultaneously, azelastine exerts a mast cell stabilizing effect by modulating cellular calcium ion concentration. This action inhibits the degranulation of mast cells, thus reducing the exocytotic release of pre-formed inflammatory mediators such as histamine, tryptase, and tumor necrosis factor-alpha. Furthermore, it modulates the de novo synthesis and release of other chemical mediators, including leukotrienes, kinins, and platelet-activating factor. The combined peripheral H1-receptor blockade and the stabilization of inflammatory cells lead to a systemic reduction in mediator-driven physiological consequences, including localized vascular permeability and neural stimulation.

Dosage and Administration Information

How Azelast is Used: Administration Guidelines

Azelastine (Azelast) is intended exclusively for local application via specific administration routes, with usage protocols structured according to its two distinct aqueous formulations. The medicine is administered via the Intranasal route (nasal spray solution) or the Ophthalmic route (eye drop solution).

Administration Routes and Schedules

The administration schedule typically involves twice daily as the frequency for most indications and forms. However, the 0.15% nasal spray formulation has a once-daily option of 2 sprays per nostril for seasonal use in adults and adolescents (12 years and older).

Usage Context Standard Adult Dosing (Typical)
Nasal Spray (0.1% or 0.15%) 1 to 2 sprays per nostril, twice daily.
Ophthalmic Solution (0.05%) 1 drop in affected eye(s), twice daily.

Procedural and Population Rules

The nasal spray device requires a priming process before initial use and if it has not been used for a specified duration. This ensures accurate dose delivery. Pediatric dosing starts at lower regimens, such as 1 spray per nostril twice daily for children 6 years and older (nasal) and 1 drop twice daily for children 3 years and older (ophthalmic).

For the ophthalmic solution, a constraint is the removal of soft contact lenses before instillation, with reinsertion permitted after a defined time interval, typically 10 minutes. Administration should adhere to the maximum dose, such as not exceeding 4 sprays per nostril in a 24-hour period for the 0.15% nasal formulation. If a dose is missed, the protocol is to resume the schedule at the next regular time without applying a double dose.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Azelast

The clinical evidence for Azelastine Hydrochloride is derived from a detailed body of randomized controlled trials (RCTs), systematic reviews, and meta-analyses, focusing on its local use for allergy-related conditions.


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Research for the nasal spray in seasonal (SAR) and perennial (PAR) allergic rhinitis relies on numerous short-term RCTs that examined outcomes related to physical discomfort. These studies tracked patient-reported scores for symptoms like runny nose, sneezing, itching, and nasal congestion. Findings describe patterns where measured symptom changes showed a measurable difference when contrasted with the changes reported for the placebo vehicle. The time to initial patient-reported symptom change following administration was quick, often reported within minutes.

Evidence for Use in Non-Allergic Vasomotor Rhinitis

For vasomotor rhinitis (VMR), Azelastine was evaluated in dedicated short-term RCTs that monitored outcomes linked to inflammatory or irritative states. Studies tracked changes using a specific Vasomotor Rhinitis Symptom Score. The findings indicated an observed variance when compared to the inactive vehicle in patient-reported outcomes describing perceived discomfort. However, the evidence is limited for this chronic condition compared to the data volume available for allergic rhinitis.


Evidence for Use in Allergic Conjunctivitis

Research for the eye drop formulation in allergic conjunctivitis includes controlled Conjunctival Antigen Challenge (CAC) models and longer-term Environmental Studies. Studies monitored patient-reported scores for eye itching (pruritus) and clinician assessments of conjunctival redness. Across these scenarios, studies reported that the measured change in eye itching scores was greater than the change reported for the placebo vehicle, with the time to initial patient-reported symptom change being quick, often within minutes.

Evidence Gaps and Areas of Ongoing Research

Research is predominantly focused on short-term changes (2–8 weeks). One key research limitation frame is the lack of fully established long-term effects and sustained outcomes beyond the 8-week period, especially regarding maintenance of outcomes reflecting daily functioning. Data for certain groups remain insufficient, particularly for children under 3 years of age, and Comparative evidence against some newer therapeutic combinations is less extensive.

Key Studies & References

  1. Label: AZELASTINE HYDROCHLORIDE spray, metered - FDA DailyMed

Frequently Asked Questions (FAQ)

Common questions about Azelast (FAQ)

Q: Is Azelast safe to use every day for a long time?

Official regulatory documents indicate that clinical trials examining the nasal spray typically evaluated use for periods up to 8 weeks (56 days).

No specific data is currently available in the official information to establish the safety or effects of using the medicine every day for periods longer than this duration.


Q: Can Azelast be used during pregnancy or while breastfeeding?

The use of Azelast during pregnancy is described as conditional in official documents, meaning it is permitted only if the potential benefit is judged to justify the potential risks.

Official information also indicates that the drug is excreted into human milk, and caution is generally recommended during the period of breastfeeding.


Q: Are there any foods or drinks that should be avoided when taking Azelast?

According to official prescribing information, concurrent use with alcohol is restricted or advised to be avoided. This is due to a risk of additive effects, which can increase drowsiness and impair mental alertness.

No specific foods are listed as mandatory restrictions or avoidance items in the regulatory documentation.


Q: Can children of all ages use Azelast?

No, the use of Azelast is restricted by specific minimum age cut-offs, which vary depending on the indication (condition) and the specific formulation used.

For example, eligibility for the nasal spray typically starts at 6 years old, while eye drops may be established for children 3 years and older for certain uses.


Q: Has Azelast been studied in older adults?

Regulatory documents indicate that the clinical trials conducted did not include a sufficient number of patients aged 65 and over.

Because of this, it is not possible to determine from the available trial data whether older patients respond differently to the medicine compared to younger adults.


Q: Is Azelast considered safe for people with liver or kidney problems?

Official guidance advises caution when the medicine is used in patients with renal impairment (kidney problems). This is a warning based on the potential for increased systemic exposure of the drug.

Information detailing specific warnings or necessary precautions for patients with liver (hepatic) impairment is not explicitly provided in the regulatory cautions.


Q: Do studies suggest Azelast helps with both short-term and long-term problems?

Studies have primarily examined the short-term effects of Azelast, typically over periods of 2 to 8 weeks, showing measurable outcomes for symptom relief.

Official research summaries note a lack of fully established data concerning the medicine's long-term effects and sustained outcomes beyond this short-term period.


Q: How long does the effect of Azelast usually last?

Azelastine is commonly prescribed on a twice-daily schedule.

Clinical studies for this regimen indicate that the measured symptom change persisted over the 12-hour dosing interval between applications, suggesting the effect is sustained throughout the scheduled dosing period.


Q: Can Azelast interact with over-the-counter pain relievers like ibuprofen?

Official regulatory prescribing information detailing drug interactions does not list a specific known interaction with over-the-counter pain relievers such as ibuprofen.

The interactions section focuses on compounds that affect the central nervous system or certain clearance pathways.


Q: What ingredients are in Azelast besides the main drug?

Yes, official regulatory information lists the inactive ingredients in the formulation besides Azelastine Hydrochloride.

These components include compounds such as benzalkonium chloride, edetate disodium, and purified water, which are included to stabilize the solution or aid in its proper delivery.


Q: Is Azelast suitable for people with high blood pressure?

According to official studies, the nasal spray formulation demonstrated minimal systemic absorption, meaning very little of the drug enters the bloodstream.

Clinical pharmacodynamic studies have shown no evidence of an effect on the electrical activity of the heart, such as the QTc interval on the electrocardiogram.


Q: Is it okay to use Azelast before going to bed?

The medicine is commonly prescribed on a twice-daily schedule, meaning one of the applications would be in the evening, often before bed.

Official safety information notes that drowsiness (somnolence) is a common side effect, which may affect mental alertness.


Q: What happens if I stop using Azelast suddenly?

Since Azelast is primarily a treatment for symptom relief (such as allergy symptoms or a runny nose), if you stop using the drug suddenly, the symptoms that the medicine was helping to manage may return.


Q: Is it common to have a dry mouth or nose when using Azelast?

Yes, dry mouth and nasal discomfort are listed as possible side effects reported by users of Azelastine nasal spray in official patient information and adverse event reports.


Q: How is the safety of Azelast tracked by government agencies?

The safety of the medicine is tracked through mandatory reporting systems called pharmacovigilance.

Official labels and patient information include clear instructions for both users and healthcare providers on how to report any suspected adverse reactions to government agencies.

How should Azelast be stored and disposed of?

How to Store and Dispose of Azelastine

Official regulations require specific conditions for storing Azelastine solutions to maintain stability and safety.

Storage Requirements

Item Requirement
Temperature Store most formulations at controlled room temperature (20 C to 25 C). Ophthalmic solution may be stored between 2 C and 25 C.
Protection The product must be protected from freezing and certain combination sprays must not be refrigerated.
Container Keep the container tightly closed and store the nasal spray upright.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal and Stability

Products have a defined in-use shelf life; for example, nasal spray must be discarded after the specified number of sprays or the eye solution after a set period post-opening (e.g., 28 days).

Dispose of unused or expired Azelastine according to local requirements and do not throw away via wastewater or household waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Azelast found in:

A-Z Index: